# DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

> **NCT00862303** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fuzhou General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** DC-CIK
- **DRUG:** IL-2/IFN-α

## Key facts

- **NCT ID:** NCT00862303
- **Lead sponsor:** Fuzhou General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2011-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862303, "DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00862303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*